Post-treatment cytotoxic immune response did not vary based on pCR and no pCR
CYTOTOXICITY
To ascertain if variances in in vitro PBMC cytotoxicity due to neo-adjuvant treatment could be associated with patient response to therapy, the in vitro cytotoxicity data was broken down by pCR. There was no change in direct cytotoxicity against the K562 or SKBR3 cell lines based on clinical response between pre- and post-treatment samples (Fig. 